

## Announcements

(Requests for announcements must be received at least three months before publication.)

### 1998 ANNUAL MEETING

The AACR's Annual Meeting is one of the largest and most important annual gatherings of scientists engaged in cancer research worldwide. The next Annual Meeting will take place in New Orleans, LA, March 28-April 1, 1998. The Chairperson of the Annual Meeting is Frank J. Rauscher III of the Wistar Institute. The Program Committee will invite outstanding scientists in the field to organize plenary sessions, symposia, controversy sessions, and meet-the-expert sunrise sessions. They also look forward to receiving for consideration for presentation the proffered papers submitted by members of the cancer research community. All abstracts must be sponsored by an AACR member in good standing. The deadline for receipt of abstracts in the AACR office will be **October 28, 1997**.

### FUTURE ANNUAL MEETINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

1999 April 10-14, Philadelphia, PA

2000 April 8-12, Los Angeles, CA

### CALL FOR NOMINATIONS FOR 1998 AACR-PEZCOLLER INTERNATIONAL AWARD FOR CANCER RESEARCH

#### AACR-Pezcoller International Award Committee

Carlo M. Croce, M.D., *Chairperson, Kimmel Cancer Center, Philadelphia, USA*

Laurent Degos, M.D., Ph.D., *University of Paris, Paris, France*

Giuseppe Della Porta, M.D., *European Institute of Oncology, Milan, Italy*

Gertrude B. Elion, D.Sc., *Glaxo Wellcome, Inc., Research Triangle Park, USA*

Judah Folkman, M.D., *Harvard Medical School, Boston, USA*

Carl-Henrik Heldin, Ph.D., *Ludwig Institute for Cancer Research, Uppsala, Sweden*

Bruce A. J. Ponder, Ph.D., *CRC Human Cancer Genetics Research Group, Cambridge, United Kingdom*

Peter K. Vogt, Ph.D., *Scripps Research Institute, La Jolla, USA, Ex officio*

David M. Livingston, M.D., *Dana-Farber Cancer Institute, Boston, USA*

Enrico Mihich, M.D., *Roswell Park Cancer Institute, Buffalo, USA*

The AACR-Pezcoller International Award for Cancer Research is given biennially to a scientist who has made a major scientific discovery in the field of cancer. The Pezcoller Foundation was established in 1982 by Professor Alessio Pezcoller, a dedicated Italian surgeon who has made important contributions to medicine during his career and who, through his foresight, vision, and generous gift in support of the formation of the Foundation, stimulated others to make significant advances in cancer research. Over the past decade the Pezcoller Foundation has given a major award for outstanding contributions to cancer and cancer-related biomedical science.

The American Association for Cancer Research (AACR) was founded in 1907 by eleven physicians and scientists dedicated to the conquest of cancer and now has over 13,000 members in more than 60 countries who are experts in basic, clinical, and translational cancer research. The AACR fulfills its mission, the communication of important scientific results, in a variety of forums including publications, meetings, and training and educational programs. Because of their joint commitment to scientific excellence in cancer research, the Foundation and the AACR have now agreed to collaborate on the presentation of this award. This will strengthen their already well-established relationship and facilitate international collaborations and interactions.

The awardee will be selected by an international committee of AACR members appointed by the AACR President with the agreement of the Council of the Pezcoller Foundation. Although normally the Award will be presented to a single investigator, in exceptional cases two individuals may be selected to share the award when their investigations have resulted in related prizer-worthy work. The committee will make its selection solely on the basis of the awardee's scientific accomplishments without regard to race, gender, nation-

ality, or religious or political views. The candidate will give an award lecture during the AACR Annual Meeting in New Orleans, USA (March 28-April 1, 1998) and will receive the award in a ceremony at the Foundation's headquarters in Trento, Italy, right after the annual meeting. The award consists of an honorarium of US \$100,000 and a commemorative plaque.

The Foundation and the AACR are now soliciting nominations for the 1998 Award. Nominations can be made by any scientist who is now or has been affiliated with an institution engaged in cancer research. Institutions or organizations are not eligible for this award, and candidates may not nominate themselves.

There is no official application form for this award. The nomination package should consist of the following:

- the candidate's curriculum vitae
- an indication of the most important references in the candidate's curriculum vitae and list of publications
- a letter of recommendation in English (500 words, maximum) describing the candidate's major scientific achievements and explaining the impact of these achievements on progress in cancer research

Nominators are asked to maintain the confidentiality of the nomination process and to refrain from informing the candidate about the nomination.

The deadline for receipt of nominations by the AACR is September 30, 1997, for consideration for the 1998 Award. Questions about the nomination process should be directed to the AACR Office via FAX at (215) 440-9313 or E-mail at [aacr@aacr.org](mailto:aacr@aacr.org). Nominators should submit the original plus 12 copies of their nominations to:

Carlo M. Croce, M.D., Chairperson, Selection Committee  
AACR-Pezcoller International Award for Cancer Research  
c/o American Association for Cancer Research, Inc.  
Public Ledger Building, Suite 826  
150 South Independence Mall  
West Philadelphia, PA 19106-3483  
USA

### CALL FOR NOMINATIONS FOR AACR AWARDS

The AACR presents six awards to distinguished scientists at its Annual Meeting. The Awards Committee, consisting of six separate subsections, will recommend candidates for each award to the AACR Executive Committee. Below you will find a description of each award. Members wishing to make nominations should provide a short description of the candidate's accomplishments; the subcommittee involved will obtain further documentation on suitable candidates. Nominations may be directed to the Association Office for forwarding to the appropriate subcommittee. This material should be received no later than September 15, 1997.

**Clowes Memorial Award.** The Eli Lilly Company established the Clowes Memorial Lecture to honor Dr. G. H. A. Clowes, who was a founding member of the AACR and a research director of Eli Lilly. The purpose of the award is to give "recognition of outstanding research accomplished in some recent period." The Clowes Award should recognize outstanding recent accomplishments in basic cancer research, and the Board of Directors construes this to mean both laboratory research and epidemiological investigations.

**Joseph H. Burchenal AACR Clinical Research Award.** Bristol-Myers Squibb has established this award to recognize outstanding achievements in clinical cancer research. It is named for Dr. Joseph H. Burchenal, past president and honorary member of the AACR, and a leading figure in the field of cancer chemotherapy. There are no restrictions on the age or geographic location of the awardee.

**Richard and Hinda Rosenthal Foundation Award.** The Rosenthal Foundation has established this award to "recognize research which has made or gives the promise of soon making a notable contribution to improved clinical care in the field of cancer." The Foundation wishes to honor and provide incentive to young investigators relatively early in their careers. It has, therefore, stipulated that the Association restrict the award to individuals who are engaged in the practice of

medicine, who reside in the Americas, and who will not be more than 50 years of age at the time of the award (March 1998).

**Rhoads Memorial Award.** In 1979, an anonymous donor established this award in memory of Dr. Cornelius P. Rhoads, a founder and the first Director of the Sloan-Kettering Institute for Cancer Research. This annual award is intended to give recognition to an "individual on the basis of meritorious achievement in cancer research." In accordance with the donor's wishes, the awardee must be a young investigator; therefore, the Board of Directors of the Association has stipulated that the recipient must not have reached his or her 41st birthday by the time of the award (March 1998).

**Cain Memorial Award.** The Warner-Lambert Company instituted this award to honor the memory of Dr. Bruce F. Cain of New Zealand for his work in the "design, synthesis, and biological evaluation of potential anticancer drugs." The purpose of the award is to "give recognition to an individual or research team for outstanding preclinical research that has implications for the improved care of cancer patients." Examples of such research include discovery of a significant new anticancer agent and major contributions to a compound's application as an antitumor agent. The award will recognize outstanding contributions in the fields of medicinal chemistry, biochemistry, or tumor biology as related to drug discovery; will encompass anticancer, antiviral, and antifungal agents; will have no age limit; and will be international in scope.

**American Cancer Society Award.** The American Cancer Society sponsors this award to honor outstanding achievements in the fields of epidemiology, biomarkers, and prevention. There are no age or geographical restrictions on the awardee.

#### AACR SPECIAL CONFERENCES IN CANCER RESEARCH

A number of meetings are now being organized in the AACR's series of smaller scientific meetings. Following are the topics, dates, locations, and program committees for these meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Nonmembers may receive this information by sending their names and addresses to Meetings Mailing List, American Association for Cancer Research, Public Ledger Building, 150 South Independence Mall West, Suite 826, Philadelphia, PA 19106-3483. Up-to-date program information is also available via the Internet at the AACR's website (<http://www.aacr.org/confmc.html>).

#### MOLECULAR GENETICS OF CANCER

Joint Meeting with European Association for Cancer Research  
September 9-12, 1997  
Hertford College, Oxford, United Kingdom

##### Chairpersons

Eric J. Stanbridge, Irvine, CA  
Walter Bodmer, Oxford, United Kingdom

#### TUMOR SUPPRESSOR GENES

Co-sponsored by the National Cancer Institute of Canada  
September 26-30, 1997  
Victoria Conference Centre, Victoria, BC, Canada

##### Chairpersons

Stephen H. Friend, Seattle, WA  
Philip Branton, Montreal, Quebec, Canada

#### TRANSCRIPTIONAL CONTROL OF PROLIFERATION, DIFFERENTIATION, AND DEVELOPMENT

October 17-21, 1997  
The Sagamore Resort, Bolton Landing (Lake George), NY

##### Chairpersons

Robert Eisenman, Seattle, WA  
Elaine V. Fuchs, Chicago, IL

#### DNA METHYLATION, IMPRINTING, AND THE EPIGENETICS OF CANCER

December 12-16, 1997  
El Conquistador Resort and Country Club, Las Croabas, PR

##### Chairpersons

Peter A. Jones, Los Angeles, CA  
Stephen B. Baylin, Baltimore, MD  
Timothy H. Bestor, New York, NY

#### MOLECULAR MECHANISMS OF APOPTOSIS REGULATION

January 9-13, 1998  
Renaissance Esmeralda Resort, Palm Springs, CA

##### Chairpersons

John C. Reed, La Jolla, CA  
Vishva M. Dixit, Ann Arbor, MI

#### ANGIOGENESIS AND CANCER

January 24-28, 1998  
Hyatt Orlando, Orlando, FL

##### Chairpersons

Judah Folkman, Boston, MA  
Michael Klagsbrun, Boston, MA

#### INNOVATIVE MOLECULAR BIOLOGY APPROACHES TO THE PREVENTION, DIAGNOSIS, AND THERAPY OF CANCER

Joint Meeting with the Japanese Cancer Association  
February 16-21, 1998  
Maui Marriott Hotel, Maui, HI

##### Chairpersons

Edward Bresnick, Worcester, MA  
Kaoru Abe, Tokyo, Japan

#### RECENT DEATH

We regret to report the death of Ms. Claudia Kosacolsky-Singer of the Boston University School of Medicine. Ms. Kosacolsky-Singer was an Associate Member of the American Association for Cancer Research.

#### CALENDAR OF EVENTS

Frontiers in Breast Cancer: A Comprehensive Symposium on Basic and Clinical Research, Diagnosis, and Therapy, September 18-19, 1997, Rockville, MD. Early registration deadline: August 14, 1997. Contact: GeneQuest Info-systems, 332 Bleecker St., Suite K-13, New York, NY 10014. Phone and Fax: (212) 737-3091; E-mail: [GeneQuest@concentric.net](mailto:GeneQuest@concentric.net).

Recombinant Therapeutic Proteins: High Efficiency Purification and Downstream Processing, September 18-19, 1997, The Westin Hotel Copley Place, Boston, MA. Contact: IBC USA Conferences, Inc., 225 Turnpike Road, Southborough, MA 01722-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: [reg@ibcusa.com](mailto:reg@ibcusa.com).

Signal Transduction Therapy: Novel Targets for Therapeutic Intervention, September 22-23, 1997, San Diego Hilton Beach and Tennis Resort, San Diego, CA. Contact: IBC USA Conferences, 225 Turnpike Road, Southborough, MA 01722-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: [inq@ibcusa.com](mailto:inq@ibcusa.com).

Transcriptional Regulation: Drug Discovery and Development, September 23-24, 1997, San Diego Hilton Beach and Tennis Resort, San Diego, CA. Contact: IBC USA Conferences, 225 Turnpike Road, Southborough, MA 01722-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: [inq@ibcusa.com](mailto:inq@ibcusa.com).

Sixth Regional Symposium on the Design and Methods of Clinical Trials, October 16–17, 1997, San Francisco, CA. Contact: Office of Continuing Medical Education, Registration Office, Room MCB-630, University of California, San Francisco, CA 94143-0742. Phone: (415) 476-5808.

Controlling the Complement System, October 16-17, 1997, Renaissance Washington DC Hotel, Washington, DC. Contact: IBC USA Conferences, 225 Turnpike Road, Southborough, MA 01772-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: inq@ibcusa.com.

Seventeenth International Symposium on the Separation of Proteins, Peptides, and Polynucleotides, October 26-29, 1997, Washington, DC. Contact: Janet Cunningham, Barr Enterprises, P.O. Box 279, Walkersville, MD 21793. Phone: (301) 898-3772; Fax: (301) 898-5596; E-mail: Janetbarr@aol.com.

Fourth Annual Conference on Apoptosis: Therapeutic Strategies for Regulating Cell Death, October 27-28, 1997, Westin Hotel Horton Plaza, San Diego, CA. Contact: IBC USA Conferences, 225 Turnpike Road, Southborough, MA 01772-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: inq@ibcusa.com.

Dana-Farber Cancer Institute's Fiftieth Anniversary Scientific Symposium, October 30-November 1, 1997, Boston, MA. Contact: Professional Meeting Planners, 5 Central Square, Suite 201, Stoneham, MA 02180. Phone: (617) 279-9887 or (800) 378-6857; Fax: (617) 279-9875; E-mail: PMPMeeting@aol.com.

Eighth Annual IBC International Conference on Antibody Engineering: New Technology, Application & Commercialization, December 3-5, 1997, Hotel del Coronado, Coronado, CA. Contact: IBC USA Conferences, 225 Turnpike Road, Southborough, MA 01772-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: inq@ibcusa.com.

International Symposium on Metastases in Head and Neck Cancer, January 15-18, 1998, Kiel, Germany. Contact: Dr. J.A. Werner or Dr. B.M. Lippert, Dept. of Otorhinolaryngology, Head and Neck Surgery, University of Kiel, Arnold-Heller-Str. 14, D-24105 Kiel, Germany. Phone: 49-431-597-2321; Fax: 49-431-597-2272; E-mail: j.a.werner@t-online.de.

Cardiovascular Health: Coming Together for the 21st Century, February 19-21, 1998, Hyatt Regency Embarcadero, San Francisco, CA. Contact: CORE Program, Attn. Greg Oliva, Department of Health Services, Mail Station #725, P.O. Box 942732, Sacramento, CA 94234-7320. E-mail: goliva@hw1.cahwnet.gov.

Advances in Oncology Nursing, February 20-21, 1998, Houston, TX. Contact: University of Texas M.D. Anderson Cancer Center, Office of Conference Services, Box 131, 1515 Holcombe Boulevard, Houston, TX 77030-4095. Phone: (713) 792-2222; Fax: (713) 794-1724; E-mail: meetings@mdacc.tmc.edu.

## Correction

We had previously described the discovery of a naturally occurring but oncogenic variant of a normally benign human papillomavirus (1). In Table 3 of that work, we described what we then believed to be errors in the previously published sequence of the prototype of HPV 11 (HPV 11P) (2). Recent resequencing of both the prototype of HPV 11P as well as the oncogenic variant, HPV 11VC, revealed that several, but not all, of the "errors" attributed to the HPV 11P sequence were actually mutations in the HPV 11VC genome. The C<sup>1783</sup>→G, G<sup>1784</sup>→C, and C<sup>7718</sup>→CGC changes in the sequence of HPV 11P have been confirmed by resequencing both strands of HPV 11P and HPV 11VC. The nucleotide changes T<sup>137</sup>→C, A<sup>186</sup>→C, C<sup>380</sup>→T, G<sup>431</sup>→A, G<sup>466</sup>→A, G<sup>662</sup>→T, and C<sup>3487</sup>→T previously reported for the HPV 11P sequence are in fact mutations in the HPV 11VC genome and should have been in Table 4 of R. McGlennen *et al.* (1). While these changes do not alter the significance of our isolation of an oncogenic variant of HPV 11, they do introduce additional amino acid alterations in the E6, E1, and E4 open reading frames that could affect the oncogenic potential of HPV 11VC. We are currently examining the effect of these mutations.

Ronald C. McGlennen  
Jyotsna Ghai  
Ronald S. Ostrow  
Kurt LaBresh  
John F. Schneider  
Anthony J. Faras  
*Institute of Human Genetics and  
Department of Microbiology  
University of Minnesota  
Minneapolis, MN 55455*

## References

1. McGlennen, R., Ghai, J., Ostrow, R., LaBresh, K., Schneider, J., and Faras, A. Cellular transformation by a unique isolate of human papillomavirus type 11. *Cancer Res.*, 52: 5872–5878, 1992.
2. Dartmann, K., Schwartz, E., Gissmann, L., and zur Hausen, H. The nucleotide sequence and genome organization of human papillomavirus type 11. *Virology*, 151: 124–130, 1986.